peptides researchAOD-9604: The Fragment 176-191 Fat-Loss Peptide Explained

In April 2007, Metabolic Pharmaceuticals — an Australian biotech then trading on the ASX — released top-line results from a 12-week Phase 2b trial of AOD-9604 in 502 obese adults. The molecule was the company's flagship asset. The press release was carefully worded. The primary endpoint, statistically significant weight loss versus placebo, was not met. The stock fell. By the end of 2008, Metabolic had effectively abandoned AOD-9604 as a weight-loss drug.

Two decades later, the same peptide sits on the formulary of every American compounding pharmacy that operates in the GLP-1 weight-loss space. The Phase 2b failure did not kill the molecule. It only changed who sells it.

What AOD-9604 Is and How the Mechanism Works#

AOD-9604 has a specific structural identity. The molecule is the C-terminal sequence of human growth hormone — amino acids 176 through 191 — with a tyrosine added at the N-terminus for stability. It is sometimes called "fragment 176-191" or HGH frag.

The biological rationale traces back to work by Frank Ng and John Bornstein in Melbourne in the late 1970s. Their group demonstrated that the C-terminal region of hGH carried much of the molecule's lipolytic activity but lacked the receptor-binding domains responsible for the IGF-1 cascade, insulin desensitization, and somatogenic signaling. The hypothesis: isolate the fat-burning tail, leave the metabolic risks behind.

Heffernan and colleagues at Monash University tested this in 2001 in obese Zucker rats. Their published work in Endocrinology showed that AOD-9604 reduced adipose mass and increased lipolytic activity in a dose-dependent manner. Critically, it did so without elevating circulating IGF-1, insulin, or glucose. The mechanism appeared selective. The animal data was strong. The translation became the question.

The hypothesized mechanism operates at the adipocyte level. AOD-9604 appears to act through the beta-3 adrenergic receptor pathway, stimulating lipolysis — the hydrolysis of stored triglycerides into free fatty acids and glycerol — while simultaneously inhibiting lipogenesis. In the Heffernan study, beta-3 knockout mice failed to respond to AOD-9604, which is the closest mechanistic confirmation available.

What this means functionally: AOD-9604 should mobilize stored fat for oxidation without triggering the broader endocrine effects of full-length growth hormone. No IGF-1 elevation. No carpal tunnel. No water retention. No glucose dysregulation. The Stier safety review published in 2013 confirmed this profile in humans across multiple Phase 1 and Phase 2 dose arms. The clean safety signal is real. The fat-loss signal is the part that did not replicate at scale.

The selectivity comes at a cost. Full-length growth hormone produces lipolysis partly through direct adipocyte signaling and partly through downstream metabolic effects of IGF-1 elevation, insulin desensitization, and altered substrate partitioning. AOD-9604 isolates the direct adipocyte signal and abandons the rest. The trade-off may explain why a molecule with such a clean mechanistic story has produced such modest clinical outcomes.

The Phase 2 Trials and the Bioavailability Question#

The clinical development story matters because it explains the gap between mechanism and outcome.

Phase 2a (2004-2006) — small dose-finding trials suggested a modest weight-loss signal in obese adults, particularly at the 1 mg oral dose. The signal was enough to justify Phase 2b expansion.

Phase 2b (2006-2007) — 502 obese adults randomized across four dose arms (1, 5, 10, 30 mg oral daily) plus placebo for 12 weeks. The primary endpoint was percent change in body weight versus placebo. The peptide failed this endpoint. Secondary endpoints around body composition showed inconsistent signals. The trial design used oral administration, which raises pharmacokinetic concerns, but Metabolic had explicitly developed the molecule for oral delivery and the trial was the program's go/no-go gate.

The negative result did not invalidate the mechanism. It demonstrated that the mechanism, as deployed in that trial, did not produce clinically meaningful weight loss in obese adults over 12 weeks. The molecule survived because the safety profile was so clean that there was no reason to retire it — it was simply repositioned.

In 2014, the FDA granted Generally Recognized as Safe (GRAS) status to AOD-9604 as a food additive ingredient. This regulatory backdoor enabled US compounding pharmacies to stock the molecule and physicians to prescribe it off-label in the absence of a drug approval. The Phase 2b failure became, paradoxically, the launching point for AOD-9604 as a clinic-prescribed compound.

The Phase 2b oral arms used 1, 5, 10, and 30 mg daily — doses far exceeding the typical 300 mcg subcutaneous protocol in clinical use today. The trial's negative result is sometimes attributed to bioavailability shortcomings of the oral route. The argument has substance and limits.

Peptides are degraded in the gastrointestinal tract by digestive proteases. Oral bioavailability of small peptides ranges from negligible to perhaps single-digit percentage points without protective formulation. Metabolic Pharmaceuticals' oral formulation work in the 2000s attempted to address this with enteric coatings and bile-salt adjuvants. Whether these strategies achieved meaningful systemic exposure was contested at the time and never fully resolved in published pharmacokinetic data.

The subcutaneous route bypasses gastrointestinal degradation. Bioavailability via subcutaneous injection of small peptides is typically 30-70% depending on the molecule, with peak plasma concentrations reached within 30-90 minutes. The 300 mcg subcutaneous dose probably produces systemic exposure comparable to a 5-10 mg oral dose accounting for first-pass loss.

This matters for interpretation. The Phase 2b failure was a trial of oral AOD-9604 at doses presumed to compensate for bioavailability loss. It is not strictly evidence that injected AOD-9604 at 300 mcg daily would also fail an obesity endpoint. It is also not evidence that the injected route would succeed — no Phase 3 obesity trial of subcutaneous AOD-9604 has been conducted at any dose. The compounded clinical use of subcutaneous AOD-9604 in 2026 operates in this evidence gap. The mechanism is plausible. The route is plausible. The trial has not been done. Users are, in effect, running individual experiments without the controls.

Dosing, Injection Logistics, and Safety#

These are anecdotal protocols from compounding clinics and physician-supervised practices. They are not validated dose-response curves from registered trials.

The standard subcutaneous dose is 300 mcg per day, administered once. Two timing protocols dominate. Pre-cardio fasted dosing — injection 15-30 minutes before fasted cardio in the morning. The rationale is that elevated free fatty acids from AOD-induced lipolysis become substrate for fasted oxidation. Anecdotally favored by physique-focused users. Pre-bed dosing — injection 30-60 minutes before sleep. The rationale rests on the natural overnight GH pulse that occurs during slow-wave sleep; some practitioners argue AOD-9604 may potentiate the lipolytic component of this pulse. Anecdotally favored by metabolic-clinic patients who tolerate it better away from training.

Cycle length in compounded protocols is typically 12 weeks on, 4 weeks off, repeated as desired. Some clinics run it continuously alongside GLP-1 therapy. There is no human pharmacokinetic data supporting one cycle structure over another. Injection sites rotate across the abdomen, thigh, and ventrogluteal region using insulin syringes (29-31 gauge, 5/16 inch). Site rotation matters because lipolysis is partly localized — repeated injection into the same site may produce visible focal fat loss, which some users desire and others find cosmetically inconsistent.

The practical execution of subcutaneous peptide injection is a learnable skill that affects outcomes more than most users appreciate. The standard injection apparatus is an insulin syringe — 29 to 31 gauge needle, 5/16 inch (8 mm) length, with a 0.3 mL or 0.5 mL barrel. The small barrel matters for dose precision at 300 mcg volumes. Reconstitution begins with bacteriostatic water, typically 2 mL added to a 5 mg vial. This produces a 2.5 mg/mL concentration. A 300 mcg dose is 0.12 mL — twelve units on a U-100 insulin syringe. The reconstituted peptide is refrigerated and stable for approximately 30 days.

Injection technique matters for absorption consistency. The needle enters perpendicular to a pinched skin fold to ensure subcutaneous (not intramuscular) placement. The injection is slow — 10 seconds for the full bolus minimizes site reactions. Site rotation across the abdomen (avoiding the umbilical region), the lateral thigh, and the ventrogluteal region prevents focal fat atrophy and maintains absorption consistency. Time of day affects practical adherence more than pharmacological outcome. The pre-cardio fasted protocol places the injection at the start of the day, before training. The pre-bed protocol places it at the end. Both have anecdotal advocates. Neither has comparative pharmacokinetic data.

The safety profile is the strongest argument for AOD-9604. The Stier review (2013) summarized data from multiple Phase 1 and Phase 2 trials totaling over 800 subject-weeks of exposure. No significant elevation of IGF-1, even at the highest doses tested — this is the central pharmacological distinction from full-length growth hormone. No glycemic disturbance; fasting glucose and insulin remained stable. No water retention or carpal tunnel symptoms. No significant adverse cardiac signals on EKG or cardiac biomarkers across the trial population. Injection site reactions occur in some users — erythema, mild pruritus, occasional bruising. These are dose-independent and resolve with site rotation. Long-term safety beyond 12 months is undocumented in human trials. The molecule has been in compounded clinical use since 2014, providing observational safety data, but observational data is not equivalent to controlled long-term trials.

Stacking, GLP-1 Combinations, and Clinical Context#

The most common AOD-9604 stack in 2026 is with a GLP-1 receptor agonist — typically semaglutide or tirzepatide, increasingly retatrutide where available.

The clinical logic, such as it is: GLP-1 agonists drive appetite suppression and produce substantial weight loss, but a portion of that loss is lean tissue. Practitioners argue AOD-9604 biases the loss toward adipose by accelerating lipolysis specifically. There is no controlled trial evidence supporting this combination — the rationale is mechanistic and clinical-anecdotal.

Other stacks circulate. AOD-9604 with BPC-157 and TB-500 is sometimes prescribed for athletes managing a recomposition phase alongside soft-tissue rehabilitation. AOD-9604 with tirzepatide appears in physician-supervised obesity programs at clinics operating in the gray zone between FDA-approved drug therapy and compounded peptide medicine. For the broader peptide landscape men should understand before stacking, the peptides for men hub maps each compound to its evidence grade.

The clinical conversation around AOD-9604 has shifted over the past five years. In 2018-2020, the molecule was marketed primarily as a standalone fat-loss intervention. In 2024-2026, the dominant clinical positioning is as an adjunct — a body-composition modifier added to a GLP-1 base. The repositioning reflects the empirical reality that AOD-9604 produces modest standalone effects but may add meaningful value in the context of substantial caloric reduction driven by GLP-1 appetite suppression.

The mechanistic argument for stacking has internal logic. GLP-1 weight loss includes 25-40% lean tissue loss without aggressive countermeasures. If AOD-9604 selectively mobilizes adipose-derived fatty acids for oxidation, it may shift the body-composition outcome favorably even when total weight loss remains GLP-1-driven. Whether this argument translates to measurable DEXA outcomes in human users remains undocumented in controlled trials. The clinical anecdote favors the combination; the trial evidence is absent.